Poly (ADP-ribose) polymerase inhibitors in cancer therapy.
10.1097/CM9.0000000000003471
- Author:
Ziqi ZHU
1
;
Yujun SHI
1
Author Information
1. Department of Pathology & Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Publication Type:Review
- MeSH:
Humans;
Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use*;
Neoplasms/genetics*;
DNA Repair/drug effects*;
Animals;
Antineoplastic Agents/therapeutic use*
- From:
Chinese Medical Journal
2025;138(6):634-650
- CountryChina
- Language:English
-
Abstract:
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have emerged as critical agents for cancer therapy. By inhibiting the catalytic activity of PARP enzymes and trapping them in the DNA, PARPis disrupt DNA repair, ultimately leading to cell death, particularly in cancer cells with homologous recombination repair deficiencies, such as those harboring BRCA mutations. This review delves into the mechanisms of action of PARPis in anticancer treatments, including the inhibition of DNA repair, synthetic lethality, and replication stress. Furthermore, the clinical applications of PARPis in various cancers and their adverse effects as well as their combinations with other therapies and the mechanisms underlying resistance are summarized. This review provides comprehensive insights into the role and mechanisms of PARP and PARPis in DNA repair, with a particular focus on the potential of PARPi-based therapies in precision medicine for cancer treatment.
